Worth Medicines India Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 24-12-2024
- Paid Up Capital ₹ 0.50 M
as on 24-12-2024
- Company Age 19 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.50 Cr
as on 24-12-2024
- Revenue -4.71%
(FY 2020)
- Profit -89.75%
(FY 2020)
- Ebitda 169.24%
(FY 2020)
- Net Worth 1.65%
(FY 2020)
- Total Assets 14.32%
(FY 2020)
About Worth Medicines India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹1.50 Cr.
Rajni Chaudhari, Manoj Chaudhary, and Swaran Chaudhry serve as directors at the Company.
- CIN/LLPIN
U24230HP2005PTC028155
- Company No.
028155
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Mar 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Himachal Pradesh
Industry
Company Details
- LocationHimachal Pradesh, Himachal Pradesh
- Telephone
- Email Address
- Website
- Social Media
What products or services does Worth Medicines India Private Limited offer?
Worth Medicines India Private Limited offers a wide range of products and services, including Ayurvedic Joint Pain Relief Medicine, Herbal Joint Pain Relief Tablets.
Who are the key members and board of directors at Worth Medicines India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajni Chaudhari  | Director | 05-Sep-2016 | Current |
| Manoj Chaudhary | Director | 24-Mar-2005 | Current |
| Swaran Chaudhry | Director | 24-Mar-2005 | Current |
Financial Performance of Worth Medicines India.
Worth Medicines India Private Limited, for the financial year ended 2020, experienced Minor drop in revenue, with a 4.71% decrease. The company also saw a substantial fall in profitability, with a 89.75% decrease in profit. The company's net worth moved up by a moderate rise of 1.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Worth Medicines India?
In 2019, Worth Medicines India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Jammu And Kashmir Bank Limited Creation Date: 28 Mar 2007 | ₹1.50 Cr | Open |
How Many Employees Work at Worth Medicines India?
Worth Medicines India has a workforce of 4 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Worth Medicines India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Worth Medicines India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
